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Preoperative platelet inhibition and
bleeding after cardiopulmonary
bypass
To the Editor:
Bizzari and associates1 studied clinical
events and potential bleeding complica-
tions in a group of patients who had under-
gone emergency or urgent cardiac surgery
after treatment with tirofiban hydrochlo-
ride. They observed that patients treated
with tirobifan had a smaller decrease in
platelet count during cardiopulmonary by-
pass; other platelet suppressants have sim-
ilar effects.2,3 Preoperative platelet inhibi-
tion will reduce the platelet loss associated
with cardiopulmonary bypass because a
preferential loss of activated platelets is
observed during the period of extracorpo-
real circulation.4,5 The hemostatic function
of the preserved platelets would, however,
be impaired by heparin-induced plasma
changes.6
The study was undertaken because of a
concern that platelet inhibition may exac-
erbate bleeding after cardiopulmonary by-
pass. We among others have demonstrated
that during cardiopulmonary bypass plate-
lets lose the ability to form large stable
aggregates (macroaggregates).6-9 This im-
pairment persists for several hours postop-
eratively.7,8 Macroaggregation is important
for platelet hemostatic function because it
gives strength to a platelet plug and paves
the way for clot retraction. As platelet mac-
roaggregation is virtually abolished during
cardiopulmonary bypass,6-9 we suggest that
additional platelet suppression is unlikely
further to impair hemostasis or increase
bleeding during the immediate postopera-
tive period. Furthermore, after cardiopul-
monary bypass platelets appear resistant to
aspirin,10 an irreversible platelet inhibi-
tor; it is therefore unlikely that even
long-acting platelet suppressants that are
administered preoperatively will signifi-
cantly impair platelets late in the postop-
erative period. This would explain why
patients who received platelet suppres-
sants shortly before undergoing surgery
using cardiopulmonary bypass did not
appear to bleed excessively when com-
pared with those who did not receive
these drugs.1-3
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Transapical aortic cannulation for
acute aortic dissection with diffuse
atherosclerosis
To the Editor:
We read with interest the article by Fukuda
and associates1 and congratulate them on
their good results. We agree that femoral
artery cannulation sometimes must be
abandoned as arterial access for cardiopul-
monary bypass. Recently we operated on
an urgent basis on a 54-year-old man with
type A acute aortic dissection. The femoral
artery could not be used as arterial access
because of tinea inguinalis. We chose the
subclavian artery instead.
We doubt the reliability of transapical
aortic cannulation in median sternotomy.
We suspect that Fukuda and associates1
happened to dodge the drawbacks of using
this procedure by mere luck, because hy-
potension during elevation of the apex, dis-
location of the cannula, incompetence of
the aortic valve, and repair of the insertion
site are usually inevitable. Insufficient
myocardial protection because of the in-
ability to clamp the ascending aorta and to
administer cardioplegic solution remains a
problem to be solved. If Fukuda and asso-
ciates1 have had experience with other
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cases with this procedure, we wonder
whether the results have always been good.
Although we have some points to be
clarified, we again congratulate Fukuda
and associates1 on their successful results
in this complicated case. In our opinion,
transapical aortic cannulation should be the
last alternative. No one can predict the re-
sults of this procedure.
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Reply to the Editor:
We thank Terada and Nakamura for their
comments regarding our work.1 Transapical
aortic cannulation was originally described in
the 1970s. However, it has been unpopular
because of similar comments by the critics.
Originally this method was used in sur-
gery for congenital heart disease or mitral
valvular disease.2 The main reason for the
use of transapical aortic cannulation today
is for surgery on diseased aorta without
intracardiac abnormality. Thus the indica-
tion for this method today is different from
that during the 1970s.
We have used transapical aortic cannu-
lation in 4 patients (2 in median sternotomy
and 2 in left thoracotomy) without any se-
rious adverse effects. Although the volume
of our experience is small, we would like to
comment on it. With respect to hypoten-
sion during elevation of the apex, its dura-
tion was quite short, and the blood pressure
recovered as soon as the apex was lowered
into normal position. Although elevation of
the apex of a beating heart can be an un-
comfortable procedure for a cardiac sur-
geon, we were accustomed to this proce-
dure from our recent experience with off-
pump coronary artery bypass grafting.
In addition, hypotension during insertion
of the cannula was advantageous to reduce
the amount of bleeding during puncture of
the apex. To prevent devastating hemorrhage
during cannulation and to avoid dislocation
of the cannula, purse-string suture with Da-
cron polyester felt was placed at the apex and
preliminary venous cannulation was per-
formed. In 2 patients the femoral artery was
cannulated as an accessory perfusion site to
the lower extremities. We evaluated aortic
regurgitation during aortic perfusion, and it
was mild on duplex scanning. Intraoperative
findings revealed a competent aortic valve
with aortic cannula positioning at the center
of the aortic orifice. Although clamping of
the ascending aorta was impossible, all 4
patients underwent replacement of the aortic
arch under deep hypothermic circulatory ar-
rest either with or without selective cerebral
perfusion, depending on the needs of each
case.
Administration of cardioplegic solution
was thus performed after the aorta was
transected under deep hypothermic arrest.
Therefore inability to administer cardiople-
gic solution was not an essential problem.
Repair of the apex was completed during
cardiac arrest, and systemic perfusion was
resumed through cannula in the graft.
We concur with Terada and Nakamura
regarding the usefulness of the axillary artery
as the first alternative access to the femoral
artery.3 We used axillary artery cannulation
in 23 of 935 patients who underwent cardiac
surgery with cardiopulmonary bypass. In the
4 patients who underwent transapical cannu-
lation, both the femoral artery and axillary
artery were inaccessible or inadequate as a
systemic perfusion site because of com-
pressed true lumen of the descending aorta,
severe obesity, or subclavian artery disease.
If a patient has these conditions, transapical
aortic cannulation is indicated. We believe
that transapical aortic cannulation is safe and
useful for such selected patients.
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Thymectomy in ocular myasthenia
gravis
To the Editor:
We read with interest the recent article by
Roberts and associates1 on thymectomy in
the treatment of ocular myasthenia gravis
(OMG). It represents an important step in
the debate concerning this issue and in the
consideration of OMG as part of a broad-
spectrum disease and not as a distinct dis-
ease.
What we know from the literature is
that the disease will progress in about 50%
of patients with initial OMG.2 On the other
hand, thymectomy is considered a main-
stay therapy for generalized myasthenia
gravis (GMG), and the best outcome is
expected in patients operated on early after
the onset of the disease.
What we should simply do is predict
when a pure OMG is an initial GMG and
offer to such patients the best treatment,
which might also include an extended
thymectomy.
Apart from the presence of a thymoma,
which makes the surgical procedure man-
datory, no clear indication for thymectomy
in OMG appears in the literature.
Only a few studies have focused on
thymectomy in OMG,1,3-5 and when pa-
tients with OMG are merged with those
with GMG, the assessment of the efficacy
of thymectomy is difficult for the combined
action of various medical therapies and for
the lack of standardized methods for as-
sessing patient status before and after sur-
gical intervention and assessing the correct
criteria of success.
A contribution to the discussion about
this topic might be derived from our expe-
rience.
From 1993 to now, 29 patients with
OMG underwent transternal extended
thymectomy at our institution. In the same
period, the same neurologist (R.R.) treated
343 patients with OMG, and consequently,
the eligibility rate for surgical treatment of
OMG was 8.5%.
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